

RESEARCH ARTICLE

Open Access

Serotonin receptor 3A polymorphism c.-42C > T is associated with severe dyspepsia

Suhreta Mujakovic^{1,4}, José JM ter Linde^{4*}, Niek J de Wit¹, Corine J van Marrewijk², Gerdine AJ Fransen³, N Charlotte Onland-Moret^{1,5}, Robert JF Laheij², Jean WM Muris³, Diederick E Grobbee¹, Melvin Samsom⁴, Jan BMJ Jansen², André Knottnerus³ and Mattijs E Numans¹

Abstract

Background: The association between anxiety and depression related traits and dyspepsia may reflect a common genetic predisposition. Furthermore, genetic factors may contribute to the risk of having increased visceral sensitivity, which has been implicated in dyspeptic symptom generation. Serotonin (5-HT) modulates visceral sensitivity by its action on 5-HT₃ receptors. Interestingly, a functional polymorphism in *HTR3A*, encoding the 5-HT₃ receptor A subunit, has been reported to be associated with depression and anxiety related traits. A functional polymorphism in the serotonin transporter (5-HTT), which terminates serotonergic signalling, was also found associated with these psychiatric comorbidities and increased visceral sensitivity in irritable bowel syndrome, which coexistence is associated with higher dyspeptic symptom severity. We investigated the association between these functional polymorphisms and dyspeptic symptom severity.

Methods: Data from 592 unrelated, Caucasian, primary care patients with dyspepsia participating in a randomised clinical trial comparing step-up and step-down antacid drug treatment (The DIAMOND trial) were analysed. Patients were genotyped for *HTR3A* c.-42C > T SNP and the 44 bp insertion/deletion polymorphism in the 5-HTT promoter (5-HTTLPR). Intensity of 8 dyspeptic symptoms at baseline was assessed using a validated questionnaire (0 = none; 6 = very severe). Sum score ≥ 20 was defined severe dyspepsia.

Results: *HTR3A* c.-42T allele carriers were more prevalent in patients with severe dyspepsia (OR 1.50, 95% CI 1.06-2.20). This association appeared to be stronger in females (OR 2.05, 95% CI 1.25-3.39) and patients homozygous for the long (L) variant of the 5-HTTLPR genotype (OR 2.00, 95% CI 1.01-3.94). Females with 5-HTTLPR LL genotype showed the strongest association (OR = 3.50, 95% CI = 1.37-8.90).

Conclusions: The *HTR3A* c.-42T allele is associated with severe dyspeptic symptoms. The stronger association among patients carrying the 5-HTTLPR L allele suggests an additive effect of the two polymorphisms. These results support the hypothesis that diminished 5-HT₃ mediated antinociception predisposes to increased visceral sensitivity of the gastrointestinal tract. Moreover, the *HTR3A* c.-42C > T and 5-HTTLPR polymorphisms likely represent predisposing genetic variants in common to psychiatric morbidity and dyspepsia.

Background

Dyspeptic symptoms are common in the general population, accounting for 3-8% of the consultations in general practice [1-3]. Although it is not a life threatening condition, dyspepsia represents a significant and costly health problem with substantial negative impact on quality of

life and health care consumption [4,5]. A variety of distinct abnormalities in gastroduodenal motility have been identified in subgroups of patients with dyspeptic symptoms. However, the correlation between the presence of dyspeptic symptoms and gastroduodenal motor dysfunction is relatively weak [6-8]. More recently, visceral hypersensitivity has been put forward as a mechanism underlying dyspeptic symptoms. Visceral hypersensitivity has been associated with the presence of dyspeptic symptoms [9], but others were not able to confirm this finding

* Correspondence: J.terLinde@umcutrecht.nl

⁴University Medical Centre Utrecht, Department of Gastroenterology & Hepatology, Utrecht, the Netherlands

Full list of author information is available at the end of the article

[10-12]. Furthermore, psychosocial factors and psychiatric morbidity are underlying risk factors for the development of dyspeptic symptoms [13]. The most common psychiatric comorbidities in patients with dyspepsia are anxiety and depressive disorders [14].

Several genetic variants have been reported to affect the risk of having dyspepsia [15-19]. The mechanism underlying the association with the C825T polymorphism in the gene encoding the G protein $\beta 3$ subunit remains to be determined [15-17]. Abnormal immune response against *H. pylori* is likely underlying the associations with RANTES promoter C-28G genotype and Toll-like receptor 2 -196 to -174 del carrier status [18,19]. There is evidence of genetic influence on other risk factors for dyspepsia, i.e. psychosocial factors and psychiatric morbidity [20]. The association between psychosocial factors, psychiatric morbidity and dyspepsia may reflect a common genetic predisposition. Furthermore, we hypothesized that genetic factors may contribute to the risk of having increased visceral sensitivity and (consequently) affect the intensity of dyspepsia.

Serotonin (5-HT) plays a key role in modulating upper gastrointestinal sensory function [21]. Besides, central alterations in 5-HT transmission are thought to have a role in anxiety and depression [22]. Therefore, genes of the serotonergic system are critical candidates in assessing the role of genetic factors in dyspeptic symptom severity. Of special interest is the 5-HT₃ receptor, as 5-HT₃ receptor antagonism reduces dyspeptic symptoms [23,24] and exerts anxiolytic effects [25]. The 5-HT₃ receptor is a ligand-gated ion channel, structured as a pentameric complex. In humans, five different subunit genes, *HTR3A-E*, have been identified [26]. The 5-HT_{3A} subunit seems to play a key role in receptor formation, since it is the only subunit that can form functional homopentamers. The other subunits only form functional heteromers with the 5-HT_{3A} subunit [26]. A functional polymorphism, c.-42C > T (rs1062613), has been identified in the *HTR3A* gene. The T allele promotes translation of the *HTR3A* transcript resulting in enhanced production of the 5-HT_{3A} subunit [27,28]. It is noteworthy that the c.-42C > T polymorphism has been reported associated with depressive disorder [27], the anxiety-related trait harm avoidance [29], and irritable bowel syndrome (IBS), a functional gastrointestinal disorder showing comorbidity with anxiety and depression and patients displaying visceral hypersensitivity [28,30].

Serotonergic signalling is terminated, peripherally and centrally, by 5-HT transporter (5-HTT) mediated uptake. A common polymorphism, a 44 base pair (bp) insertion/deletion, has been described in the promoter (transcriptional control region) of the *5-HTT* gene. This polymorphism, 5-HTTLPR, creates a long (L) and a short (S) allele [31]. Homozygosity for the short variant and

heterozygosity result in reduced transcription, less protein expression and less reuptake of serotonin [32]. The 5-HTTLPR S allele has been found associated with increased visceral sensitivity in IBS [33] and with depression and anxiety related traits [34,35].

Based on this information, it can be hypothesised that polymorphisms in *HTR3A* and *5-HTT* genes might influence the sensory processes in the upper GI tract and affect dyspeptic symptom generation and reporting. In the present study we aimed to investigate the association between functional polymorphisms in these genes and dyspeptic symptom severity in primary care patients with uninvestigated dyspepsia. This association was studied in the knowledge that psychosocial comorbidity, IBS and coping styles should be included as potential confounders.

Methods

Study population

We performed a cross-sectional analysis of patients consulting with dyspepsia included in a large multicenter randomised treatment trial in primary care (DIAMOND trial). All patients included were consulting their General Practitioner with a new episode of dyspepsia, without alarm symptoms. They represent patients with dyspepsia managed in primary care. Details of the study design have been described elsewhere [36]. The study has been approved by the Medical Ethics Committees of the University Medical Centres Utrecht, Maastricht and Nijmegen.

Patients were enrolled after giving written informed consent. All data used for this study were registered at inclusion, before starting dyspepsia treatment. Self-reported questionnaires regarding gastrointestinal symptoms, demographic data (age, gender and ethnicity) psychopathology, life style factors; current smoker (yes/no) and current alcohol consumption (yes/no), use of co-medications, Irritable bowel syndrome (IBS) status (self reported; yes/no) were obtained at baseline. One blood sample was drawn for DNA extraction and determination of genotypes.

Dyspeptic symptoms were classified with a dyspepsia symptom questionnaire, validated by Veldhuyzen van Zanten [37]. It covers eight essential dyspeptic symptoms: epigastric pain, belching, heartburn, bloating, flatulence, regurgitation, nausea and halitosis. Severity of symptoms was registered on a 7 point Likert scale graded: (0) none, (1) minimal, (2) mild, (3) moderate, (4) moderately severe, (5) severe, (6) very severe. The symptom severity score is calculated by the sum of all items (range 0-48). Patients were classified as having mild, moderate and severe symptoms based on tertiles in the mean symptom score. Severe dyspeptic symptoms were defined as score ≥ 20 .

Psychological problems were assessed using a validated Dutch version of SCL-90 questionnaire consisting of

90 questions about 9 dimensions of psychological state [38]. In this analysis we used the SCL-90 dimension “psycho-neuroticism” which summarizes psychic dysfunction (calculated as a sum of all questions divided by the number of dimensions).

Coping styles were measured by a short version of the Utrecht Coping Questionnaire consisting of 17 items [39]. Six coping styles are distinguished, classified as: active coping, seeking support, avoidance coping, palliative coping, religious coping and passive reaction. Coping styles were rated on a four-point Likert scale ranging from (1) seldom or never, (2) sometimes, (3) often and (4) very often. Scale scores are the sums of the individual items. Higher scores indicate that the specific coping style is more often adopted.

Genotyping

Genomic DNA was extracted from whole blood using the QIAamp DNA blood minikit (Qiagen, Hilden, Germany). Genotyping of the *HTR3A* c.-42C > T polymorphism (rs1062613) was performed by Molecular Beacon assay using the iCycler iQ real-time PCR detection system (BioRad, Hercules, CA, USA). The assay was carried out in a total volume of 25 µl, containing 50 ng of genomic DNA, 12.5 µl 2× iQ Supermix (BioRad, Hercules, CA, USA), 1000 nM of forward primer (5'-GCAGCCTCA-GAAGGTGTG-3'), 250 nM of reverse primer (5'-CAGTTGAAGTCGTCGTAGCC-3') and 400 nM of each molecular beacon. MgCl₂ was added to obtain a final concentration of 4 mM. Sequences of the molecular beacons were 5'-FAM-CGGACCAGTGCTCAGGGCGAGGCGGTCCG-DABCYL-3' (C-allele specific) and 5'-TXR-CGC GACCGAGTGCTCAGGACGAGGCTGGTCGCG-DABCYL-3' (T-allele specific). The PCR thermal cycling protocol applied consisted of an initial denaturation and enzyme activation step of 95°C for 3 min, followed by 40 cycles of 95°C for 30 s, 60°C for 1 min and 72°C for 45 s. In each run several controls were included: a “no template” control to check for contamination of reagents and positive controls for all three genotypes. To validate genotyping of *HTR3A* c.-42C > T by molecular beacon assay, sequencing was performed in a set of randomly chosen patients; concordance was 100%.

Genotyping of 5-HTTLPR polymorphism was performed by PCR and subsequent agarose gel electrophoresis. PCR was performed using the primers described by Camilleri et al [40]. The assay was carried out in a total volume of 25 µl, containing 50 ng of genomic DNA, 12.5 µl GC buffer I, 4.0 µl dNTP mix (2.5 mM each), 200 nM of each primer and 0.25 µl TaKaRa LA Taq polymerase (5 U/µl). The PCR thermal cycling protocol applied consisted of an initial denaturation step of 94°C for 1 min, followed by 30 cycles of 94°C for 30 s, 60°C for 30 s, 72°C for 2 min and a final extension step at 72°C

for 5 min. The size of the amplified fragments was determined by electrophoresis on a 2.5% low range ultra agarose gel (Biorad, Hercules, CA, USA) stained with ethidium bromide; 572 bp and 528 bp products were typed as long (L) and short (S) alleles respectively.

Data analysis

Severity of dyspeptic symptoms was dichotomised as a sum score of ≥20 yes/no. Age was categorised as < 45 and ≥ 45 years.

The genotype distributions for the *HTR3A* c.-42C > T and 5-HTTLPR polymorphisms were tested for Hardy-Weinberg equilibrium using the Chi square test. *In vitro* studies have revealed that both the heterozygous (LS) and homozygous S genotypes of 5-HTTLPR result in reduced 5-HTT protein expression and uptake of serotonin [32]. Therefore, for 5-HTTLPR S allele carriers were analyzed versus subjects with the LL genotype. The significant difference in amygdaloidal activity in subjects with CC and CT genotypes of *HTR3A* c.-42C > T suggests a dominant effect of the T allele [41]. Therefore, we have analysed the CC genotype versus the combined homozygous and heterozygous T genotype.

Chi square test was used to test differences in genotype distributions, demographic, lifestyle and biologic factors, between patients with severe dyspepsia and mild and moderate dyspepsia. To assess association between genotype and phenotype logistic regression model with severe dyspeptic symptoms (yes/no) as dependent variable was used. For this model adjustments were made for age, IBS status, psycho neuroticism, use of antidepressants, use of acid suppressive medication and active coping style. Confounding effect by gender, psycho neuroticism, 5-HTTLPR genotype, alcohol use and smoking status was evaluated using stratified analyses.

To avoid bias due to race related differences in genotype distribution we excluded non Caucasian patients from the analysis. To prevent bias from missing values (4-15%) due to full or partial non response, regression method was used to impute missing values on the items of SCL-90, gastrointestinal symptom questionnaire, and other covariates.

All statistical analyses were performed with SPSS for Windows, version 14.0. P values less than the respective significance thresholds, obtained by applying Bonferroni correction for multiple testing, were considered statistically significant.

Results

From the 664 patients included in the DIAMOND study, 625 (94.1%) were of Caucasian origin. Blood samples for genotyping were obtained from 592 patients (94.7%). Between 20-30% of the patients graded their symptoms as mild to moderate (Table 1). Patients with severe

Table 1 Overview and grading of dyspeptic symptoms (%) in the study population

Symptom	Absent	Minimal	Mild	Moderate	Moderately Severe	Severe	Very Severe
Epigastric pain	14.3	11.1	26.5	30.4	13.9	3.2	0.6
Heartburn	16.0	12.3	19.4	22.7	20.1	6.3	3.2
Regurgitation	17.2	14.1	25.3	21.5	15.1	4.7	2.1
Nausea	35.8	22.3	22.1	9.2	6.6	2.9	1.1
Bloating	14.2	13.8	23.2	21.7	19.0	6.2	2.0
Belching	12.9	16.7	25.3	21.4	15.7	5.6	2.4
Flatulence	10.2	17.8	30.7	22.0	13.7	4.5	1.1
Halitosis	42.0	25.6	16.4	8.6	3.6	2.4	1.4

dyspepsia were younger ($p < 0.05$) and had higher level of psycho neuroticism ($p < 0.05$) than patients with mild and moderate dyspepsia (Table 2). No significant difference was observed regarding gender, smoking behaviour and IBS co morbidity, as well as alcohol consumption and co-medication use.

The genotype distributions of *HTR3A* c.-42C > T and 5-HTTLPR were in concordance with Hardy-Weinberg equilibrium (Table 3). *HTR3A* c.-42T allele was more prevalent among patients with severe dyspepsia (45.2 vs. 35.7%); the OR for association was 1.50 (95% CI 1.06-2.20). The association did not remain significant after

Bonferroni correction for multiple testing (significance threshold $P = 0.025$). There was no association of 5-HTTLPR genotype considered as a single factor with dyspeptic symptom severity (Table 3).

To determine whether gender, 5-HTTLPR genotype, smoking and alcohol consumption and psycho neuroticism modify the effect of *HTR3A* c.-42C > T genotype on dyspeptic symptoms we stratified for these factors. A significantly increased risk was found in females (OR 2.05, 95% CI 1.25-3.39) and in patients with 5-HTTLPR LL genotype (OR 2.00, 95% CI 1.01-3.94) (Table 4). The influence of female gender remained significant after

Table 2 Patients characteristics according to dyspeptic symptom severity

		Severe dyspeptic symptoms	
		Yes	No
Number		197 (33.3)	395 (66.7)
Age, years	< 45	108 (54.8)	151 (38.2)
	≥ 45	89 (45.2)	244 (61.8)
Gender	Male	84 (42.6)	186 (47.1)
	Female	113 (57.4)	209 (52.9)
Current alcohol use	Yes	149 (75.6)	295 (74.7)
	No	48 (24.4)	100 (25.3)
Current smoking	Yes	59 (29.9)	101 (25.6)
	No	138 (70.1)	294 (74.4)
IBS	Yes	10 (5.1)	17 (4.3)
	No	187 (94.9)	378 (95.7)
Co-medication	No	123 (62.4)	265 (67.0)
	Antacids	47 (23.9)	68 (17.2)
	NSAIDs	24 (12.2)	65 (16.4)
	Antidepressants	17 (8.6)	19 (4.8)
Psycho neuroticism	Yes	95 (48.2)	107 (27.1)
	No	102 (51.8)	288 (72.9)
Coping style	Active coping	13.9	13.3
	Seeking support	11.7	11.1
	Avoidance coping	3.9	3.7
	Palliative coping	4.7	4.4
	Religious coping	3.2	3.0
	Passive reaction	2.0	2.0

Data presented as number (%) except for coping style, which values represent mean scores.

Table 3 Association of *HTR3A* c.-42C > T and 5-HTTLPR genotypes with dyspeptic symptom severity

Polymorphism	Genotype	Total N = 592	Severe dyspeptic symptoms		OR (95% CI) *	P value
			Yes N = 197	No N = 395		
<i>HTR3A</i> c.-42C>T	CC	362 (61.1)	108 (54.8)	254 (64.3)	1.00	0.027
	CT	200 (33.8)				
	TT	30 (5.1)				
	CT + TT	230 (38.9)	89 (45.2)	141 (35.7)	1.50 (1.06-2.20)	
5-HTTLPR	LL	170 (28.7)	59 (29.9)	111 (28.1)	1.00	0.60
	LS	310 (52.4)				
	SS	112 (18.9)				
	LS + SS	422 (71.2)	138 (70.1)	284 (71.9)	0.90 (0.60-1.40)	

Genotype distributions are depicted as number (%).

*adjusted for age, IBS status, psycho neuroticism, use of anti depressive and acid suppressive medication and active coping style.

Bonferroni correction for multiple testing, whereas the 5-HTTLPR LL effect did not (significance threshold $P = 0.0125$). The additive effect of homozygous L 5-HTTLPR genotype appeared to be more pronounced in females (OR 3.50, 95% CI 1.37-8.90) (Table 5), which was also significant after Bonferroni correction for multiple testing (significance threshold $P = 0.0125$).

Discussion

The results of this study suggest that patients carrying the *HTR3A* c.-42T allele are at increased risk of having severe dyspeptic symptoms. This risk seems to be even higher for women and patients homozygous for the 5-HTTLPR L allele.

The association could be explained as follows; Noxious and non-noxious visceral sensations are carried by extrinsic primary afferents to the dorsal horn of the spinal cord. Sensory transmission in the spinal dorsal horn is attenuated by endogenous inhibitory systems that originate at the brainstem. One of the main descending systems to the spinal dorsal horn is serotonergic [42]. 5-HT₃ receptors present on spinal inhibitory interneurons

receive input from the descending serotonergic fibers. Activation of these 5-HT₃ receptors evokes release of GABA, which in turn reduces the excitability of dorsal horn neurons [43]. Consequently, the output of visceral sensory information to the brainstem and thereby symptom perception is reduced. It has been demonstrated in a model of visceral pain that 5-HT₃ receptors in the spinal cord mediate antinociception [44]. The *HTR3A* c.-42T allele promotes translation of the *HTR3A* transcript resulting in enhanced production of the 5-HT_{3A} subunit [27,28]. *In vitro* experiments indicate that homomeric 5-HT_{3A} receptors have lower affinity for 5-HT and desensitize more rapidly as compared to heteromeric 5-HT_{3AB} receptors [45]. Consistently, it has been found in *5-HTT* knockout mice, in which 5-HT availability at the receptor is enhanced, that the expression of 5-HT₃ subunits is altered, apparently leading to a relatively increased proportion of homomeric 5-HT_{3A} receptors [46]. Thus, the increased expression of 5-HT_{3A} subunits in *HTR3A* c.-42T allele carriers may result in a higher proportion of homomeric 5-HT_{3A} receptors and as a consequence decreased response to 5-HT of the 5-HT₃ receptor

Table 4 Association between severe dyspeptic symptoms and *HTR3A* c.-42C > T genotype stratified by gender and 5-HTTLPR genotype

	Severe dyspeptic symptoms	<i>HTR3A</i> c.-42C>T		OR (95% CI) *	P value
		CC	CT + TT		
Gender					
Female	Yes	56 (49.6)	57 (50.4)	2.05 (1.25-3.39)	0.005
	No	137 (65.6)	72 (34.4)		
Male	Yes	52 (61.9)	32 (38.1)	1.05 (0.60-1.84)	0.86
	No	117 (62.9)	69 (37.1)		
5-HTTLPR					
LL	Yes	31 (52.5)	28 (47.5)	2.00 (1.01-3.94)	0.046
	No	77 (69.4)	34 (30.6)		
LS + SS	Yes	77 (55.8)	61 (44.2)	1.38 (0.88-2.15)	0.15
	No	177 (62.3)	107 (37.7)		

Genotype distributions are depicted as number (%).

*adjusted for age, IBS status, psycho neuroticism, use of anti depressive and acid suppressive medication and active coping style

Table 5 Association between severe dyspeptic symptoms and *HTR3A* c.-42C > T genotype stratified by 5-HTTLPR genotype in females and males

Gender	5-HTTLPR	Severe dyspeptic symptoms	<i>HTR3A</i> c.-42C>T		OR (95% CI)	P value
			CC	CT + TT		
Female	LL	Yes	16 (45.7)	19 (54.3)	3.50 (1.37-8.90)	0.009
		No	45 (75.0)	15 (25.0)		
	LS + SS	Yes	40 (51.3)	38 (48.7)	1.70 (0.93-3.14)	0.090
		No	92 (61.7)	57 (38.3)		
Male	LL	Yes	15 (62.5)	9 (37.5)	0.96 (0.32-2.89)	0.94
		No	32 (63.0)	19 (37.0)		
	LS + SS	Yes	37 (62.0)	23 (38.0)	1.16 (0.59-2.28)	0.66
		No	85 (63.0)	50 (37.0)		

Genotype distributions are depicted as number (%).

*adjusted for age, IBS status, psycho neuroticism, use of anti depressive and acid suppressive medication and active coping style

involved in the descending antinociceptive pathway reflected in higher symptom severity. The additive effect of the LL genotype of the 5-HTTLPR polymorphism is conceivable as homozygosity for the long allele results in more rapid re-uptake of 5-HT and earlier termination of 5-HT induced signalling. As a consequence activation of the 5-HT₃ receptor on inhibitory interneurons in the spinal cord is even more diminished; this reduces antinociception.

The association between severe dyspeptic symptoms and the *HTR3A* c.-42C > T and 5-HTTLPR genotypes appears to be stronger in females than in males. A possible explanation for this finding would be different availability of serotonin in males and females. It has been shown that ovarian hormones regulate the expression of tryptophan hydroxylase (rate-limiting enzyme of serotonin synthesis), 5-HTT and inhibitory 5-HT_{1A} autoreceptors [47]. Lack of control for the variations in female sex hormones during the menstrual cycle, use of hormone replacement therapy and hormonal contraception has likely confounded many of the reported findings of gender differences in indices of serotonin availability. Interestingly, an *in vivo* investigation with positron emission tomography and α -[¹¹C]methyl-L-tryptophan trapping as a proxy for brain serotonin synthesis, showed a lower rate in healthy women compared to men [48]. Although the pre-menopausal women were studied in the same phase of the menstrual cycle, post-menopausal women were also included. The latter may have affected the extent of the reported difference in men and women. Moreover, this finding in healthy subjects does not necessarily reflect the situation in individuals with dyspepsia. Anyhow, a lower rate of serotonin synthesis in women coincides with a lower level of 5-HT available for receptor activation in females, which is consistent with reduced 5-HT₃ receptor mediated antinociceptive effects.

In short, the presence of a 5-HT₃ receptor with lower response to 5-HT due to polymorphism, rapid 5-HT re-

uptake by 5-HTT and less serotonin available for receptor activation due to gender differences in 5-HT synthesis predisposes to increased perception of visceral stimuli. The influence of the *HTR3A* c.-42C > T genotype has also been evaluated in (female) patients with irritable bowel syndrome (IBS) [30]. In contrast to what one might expect, since both dyspeptic and IBS symptoms have a visceral sensitivity component, the CC genotype appeared to be associated with greater IBS severity. Enhanced activity of amygdala-related emotional arousal circuits has been implicated in the pathophysiology of IBS [49]. Consistent with a study in healthy subjects, in IBS CC genotype subjects showed increased amygdala responsiveness to emotional facial stimuli compared with T carriers [30,41]. Activation of 5-HT₃ receptors on GABAergic interneurons innervating the amygdala exerts an inhibitory influence on amygdala reactivity, whereas those on excitatory interneurons have the opposite effect [50]. The finding of lower amygdala reactivity in T carriers was interpreted as T-allele-related increased expression of 5-HT₃ receptors on GABAergic interneurons resulting in greater inhibition of the amygdala [30,41]. These associations and interpretation of increased 5-HT_{3A} subunit expression appear in conflict with our findings, but 5-HT₃ receptor subunit composition may vary in the different regions of the central nervous system as well as the influence of 5-HT₃ receptors on excitatory interneurons. Moreover, in dyspepsia increased amygdala responsiveness may be secondary to decreased spinal antinociception. It is noteworthy that another study in patients with IBS suggests that the *HTR3A* c.-42T allele is associated with the diarrhea-predominant phenotype of the disease [28]. Patients with this phenotype seem to be more often affected by visceral hypersensitivity [51]. Furthermore, the *HTR3A* c.-42T allele was found to be associated with visceral hypersensitivity in patients with gastroesophageal reflux disease [52].

The *HTR3A* c.-42C > T polymorphism likely represents a predisposing genetic variant in common to psychiatric disorders and dyspepsia. Recently, effects of the *HTR3A* c.-42C > T genotype on emotional brain correlates of susceptibility to depression have been reported [53]. Furthermore, in healthy subjects and patients with IBS the CC genotype was found to be associated with greater anxiety ratings [30] and in Caucasians the C-allele was associated with elevated scores for the anxiety-related trait harm avoidance [29]. Although anxiety is comorbid with dyspepsia, our findings indicate that in dyspepsia the opposite allele is associated with greater overall symptom severity. Additional research is needed to directly examine the relationship between *HTR3A* c.-42C > T polymorphism and anxiety in patients with dyspepsia.

To appreciate results of this study several limitations should be mentioned. To date, most studies on 5-HT₃ receptor composition and function have been performed *in vitro* or in rodents, which lack expression of the *HTR3C*, *D*, and *E* subunits [26]. It is not known yet how native receptors in humans are composed, including the 5-HT₃ receptors on spinal inhibitory interneurons. Also the consequences of increased expression of 5-HT_{3A} subunits for receptor composition and antinociceptive function have not been assessed *in vivo*. Secondly, there is a possibility that association between *HTR3A* c.-42T allele and severe dyspeptic symptoms is due to the effect of some other polymorphism, even in another gene, which is in linkage disequilibrium with *HTR3A* c.-42C > T. Indeed, the serotonin receptor subunit gene *HTR3B* maps in close proximity to *HTR3A* and the possibility has been raised that the *HTR3A* c.-42C > T polymorphism is not the susceptibility variant but a common variant in *HTR3B*, found to be associated with depression in Japanese [54]. Furthermore, we could not discriminate between patients with organic and functional dyspepsia. This could influence the results if the association would be specific only for one of them. In this respect it has to be mentioned that previously no significant association of *HTR3A* c.-42C > T and 5-HTTLPR polymorphisms with dyspeptic symptoms was detected in tertiary referral patients [17]. In the latter study organic disease was excluded, but we believe that the discrepant results can be explained by taking into account not merely the presence but also the severity of dyspeptic symptoms in the current study.

Conclusions

The results of this study suggest that there is an association between *HTR3A* c.-42T allele and severe dyspeptic symptoms. Altered 5-HT₃ receptor function alone or in combination with 5-HTTLPR genotype could explain symptom severity in a subgroup of patients. The associations may be explained by the increased susceptibility to visceral hypersensitivity of the gastrointestinal tract and/or

increased risk of having psychiatric comorbidity. Further research will have to replicate this result and clarify the clinical consequences of it.

Acknowledgements

We thank the general practitioners for including patients in the DIAMOND trial and are grateful to all the patients who participated.

Funding

This study was funded by the Netherlands Organisation for Health Research and Development (NWO ZonMw), grant number 945-03-052. The funding organization had no involvement in study design, collection, analysis and interpretation of data, writing of the manuscript or in the decision to submit the manuscript for publication.

Author details

¹University Medical Centre Utrecht, Julius Centre for Health Sciences and Primary Care, Utrecht, the Netherlands. ²University Medical Centre St. Radboud, Department of Gastroenterology & Hepatology, Nijmegen, the Netherlands. ³Maastricht University Medical Centre, Research Institute CAPHRI, Department of General Practice, Maastricht, the Netherlands. ⁴University Medical Centre Utrecht, Department of Gastroenterology & Hepatology, Utrecht, the Netherlands. ⁵University Medical Centre Utrecht, Department of Medical Genetics-DBC, the Netherlands.

Authors' contributions

SM, NJW, CJM, GAJF, RJFL, JWMM, and MEN designed the study. SM, CJM, and GAJF obtained the blood samples and questionnaire data. Laboratory work was undertaken by SM and JJML. SM, JJML, NJW, DEG, and MEN analyzed the data and wrote the first draft of the paper. SM and CO carried out the statistical analysis. All authors contributed to and approved the final version of the manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 10 February 2011 Accepted: 20 October 2011

Published: 20 October 2011

References

1. Van Bommel MJ, Numans ME, de Wit NJ, Stalman WA: Consultations and referrals for dyspepsia in general practice—a one year database survey. *Postgrad Med J* 2001, **77**:514-8.
2. Maconi G, Tosetti C, Stanghellini V, Bianchi Porro G, Corinaldesi R: Dyspeptic symptoms in primary care. An observational study in general practice. *Eur J Gastroenterol Hepatol* 2002, **14**:985-90.
3. Meineche-Schmidt V, Krag E: Dyspepsia in general practice in Denmark. A 1-year analysis of consultants in general practice. *Scand J Prim Health Care* 1998, **16**:216-21.
4. El-Serag HB, Talley NJ: Health-related quality of life in functional dyspepsia. *Aliment Pharmacol Ther* 2003, **18**:387-93.
5. Halder SL, Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ: Impact of functional gastrointestinal disorders on health-related quality of life: a population-based case-control study. *Aliment Pharmacol Ther* 2004, **19**:233-42.
6. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J: Role of impaired gastric accommodation to a meal in functional dyspepsia. *Gastroenterology* 1998, **115**:1346-52.
7. Kim DY, Delgado-Aros S, Camilleri M, Samsom M, Murray JA, O'Connor MK, Brinkmann BH, Stephens DA, Lighvani SS, Burton DD: Noninvasive measurement of gastric accommodation in patients with idiopathic nonulcer dyspepsia. *Am J Gastroenterol* 2001, **96**:3099-3105.
8. Sarnelli G, Caenepeel P, Geypens B, Janssens J, Tack J: Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. *Am J Gastroenterol* 2003, **98**:783-8.
9. Tack J, Caenepeel P, Fischler B, Piessevaux H, Janssens J: Symptoms associated with hypersensitivity to gastric distension in functional dyspepsia. *Gastroenterology* 2001, **121**:526-35.

10. Mertz H, Fullerton S, Naliboff B, Mayer EA: **Symptoms and visceral perception in severe functional and organic dyspepsia.** *Gut* 1998, **42**:814-22.
11. Rhee PL, Kim YH, Son HJ, Kim JJ, Koh KC, Paik SW, Rhee JC, Choi KW: **Evaluation of individual symptoms cannot predict presence of gastric hypersensitivity in functional dyspepsia.** *Dig Dis Sci* 2000, **45**:1680-4.
12. Boeckstaens GE, Hirsch DP, Kuiken SD, Heisterkamp SH, Tytgat GN: **The proximal stomach and post-prandial symptoms in functional dyspeptics.** *Am J Gastroenterol* 2002, **97**:40-8.
13. Van Oudenhove L, Vandenbergh J, Geeraerts B, Vos R, Persoons P, Fischler B, Demyttenaere K, Tack J: **Determinants of symptoms in functional dyspepsia: gastric sensorimotor function, psychosocial factors or somatisation?** *Gut* 2008, **57**:1666-73.
14. Barry S, Dinan TG: **Functional dyspepsia: Are psychosocial factors of relevance?** *World J Gastroenterol* 2006, **12**:2701-7.
15. Holtmann G, Siffert W, Haag S, Mueller N, Langkafel M, Senf W, Zotz R, Talley NJ: **G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia.** *Gastroenterology* 2004, **126**:971-9.
16. Camilleri CE, Carlson PJ, Camilleri M, Castillo EJ, Locke GR, Geno DM, Stephens DA, Zinsmeister AR, Urrutia R: **A study of candidate genotypes associated with dyspepsia in a U.S. community.** *Am J Gastroenterol* 2006, **101**:581-92.
17. Van Lelyveld N, ter Linde JJM, Schipper M, Samsom M: **Candidate genotypes associated with functional dyspepsia.** *Neurogastroenterol Motil* 2008, **20**:767-73.
18. Tahara T, Shibata T, Yamashita H, Hirata I, Arisawa T: **The role of RANTES promoter polymorphism in functional dyspepsia.** *J Clin Biochem Nutr* 2009, **45**:217-23.
19. Tahara T, Shibata T, Wang F, Yamashita H, Hirata I, Arisawa T: **Genetic polymorphisms of molecules associated with innate immune responses, TLR2 and MBL2 genes in Japanese subjects with functional dyspepsia.** *J Clin Biochem Nutr* 2010, **47**:217-23.
20. Kendler KS, Gardner CO, Gatz M, Pedersen NL: **The sources of co-morbidity between major depression and generalized anxiety disorder in a Swedish national twin sample.** *Psychological Medicine* 2007, **37**:453-62.
21. Tack J, Sarnelli G: **Serotonergic modulation of visceral sensation: upper gastrointestinal tract.** *Gut* 2002, **51**(Suppl 1):i77-80.
22. Urani A, Chourbaji S, Gass P: **Mutant mouse models of depression: Candidate genes and current mouse lines.** *Neurosci Biobehav Rev* 2005, **29**:805-28.
23. Feinle C, Read NW: **Ondansetron reduces nausea induced by gastroduodenal stimulation without changing gastric motility.** *Am J Physiol Gastrointest Liver Physiol* 1996, **271**:G591-7.
24. Talley NJ, van Zanten SV, Saez LR, Dukes G, Perschy T, Heath M, Kleoudis C, Mangel AW: **A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia.** *Aliment Pharmacol Ther* 2001, **15**:525-37.
25. Rajkumar R, Mahesh R: **The auspicious role of the 5-HT₃ receptor in depression: a probable neuronal target?** *J Psychopharmacol* 2010, **24**:455-69.
26. Walstab J, Rappold G, Niesler B: **5-HT₃ receptors: role in disease and target of drugs.** *Pharmacol Ther* 2010, **128**:146-69.
27. Niesler B, Flohr T, Nöthen MM, Fischer C, Rietschel M, Franzek E, Albus M, Propping P, Rappold GA: **Association between the 5'UTR variant C178T of the serotonin receptor gene HTR3A and bipolar affective disorder.** *Pharmacogenetics* 2001, **11**:471-5.
28. Kapeller J, Houghton LA, Mönnikes H, Walstab J, Möller D, Bönisch H, Burwinkel B, Autschbach F, Funke B, Lasitshka F, Gassler N, Fischer C, Whorwell PJ, Atkinson W, Fell C, Büchner KJ, Schmidtman M, van der Voort I, Wisser A-S, Berg T, Rappold G, Niesler B: **First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome.** *Hum Mol Genet* 2008, **17**:2967-77.
29. Melke J, Westberg L, Nilsson S, Landen M, Soderstrom H, Baghaei F, Rosmond R, Holm G, Björntorp P, Nilsson L-G, Adolffsson R, Eriksson E: **A polymorphism in the serotonin receptor 3A (HTR3A) gene and its association with harm avoidance in women.** *Arch Gen Psychiatry* 2003, **60**:1017-23.
30. Kilpatrick LA, Labus JS, Coveleskie K, Hammer C, Rappold G, Tillisch K, Bueller JA, Suyenobu B, Jarcho JM, McRoberts JA, Niesler B, Mayer EA: **The HTR3A polymorphism c.-42C > T is associated with amygdala responsiveness in patients with irritable bowel syndrome.** *Gastroenterology* 2011, **140**:1953-51.
31. Heils A, Teufel A, Petri S, Stöber G, Riederer P, Bengel D, Lesch KP: **Allelic variation of human serotonin transporter gene expression.** *J Neurochem* 1996, **66**:2621-4.
32. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Müller CK, Hamer DH, Murphy DL: **Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region.** *Science* 1996, **274**:1527-31.
33. Camilleri M, Busciglio I, Carlson P, McKinzie S, Burton D, Baxter K, Ryks M, Zinsmeister AR: **Candidate genes and sensory functions in health and irritable bowel syndrome.** *Am J Physiol Gastrointest Liver Physiol* 2008, **295**:219-25.
34. Kendler KS, Kuhn JW, Vittum J, Prescott CA, Riley B: **The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication.** *Arch Gen Psychiatry* 2005, **62**:529-35.
35. Sen S, Burmeister M, Ghosh D: **Meta-analysis of the association between the serotonin transporter promoter polymorphism (5-HTTLPR) and anxiety-related personality traits.** *Am J Med Genet B Neuropsychiatr Genet* 2004, **127**:85-9.
36. van Marrewijk CJ, Mujakovic S, Franssen GA, Numans ME, de Wit NJ, Muris JW, van Oijen MG, Jansen JB, Grobbee DE, Knottnerus JA, Laheij RJ: **Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H₂-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial.** *Lancet* 2009, **373**:215-25.
37. Junghard O, Lauritsen K, Talley NJ, Wiklund IK: **Validation of seven graded diary cards for severity of dyspeptic symptoms in patients with non-ulcer dyspepsia.** *Eur J Surg Suppl* 1998, **583**:106-11.
38. Arrindell WA, Ettema JHM: **SCL-90. Symptom checklist. Handleiding bij een multidimensionele psychopathologie-indicator.** Swets Test Publishers, Lisse; 2003.
39. Schreurs PJG, van de Willige G, van de Brosshot JF, Tellegen B, Graus GMH: **De Utrechtse Coping Lijst (Utrecht Coping Questionnaire).** Swets and Zeitlinger, Lisse; 1993.
40. Camilleri M, Atanasova E, Carlson PJ, Ahmad U, Kim HJ, Viramontes BE, McKinzie S, Urrutia R: **Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome.** *Gastroenterology* 2002, **123**:425-32.
41. Iidaka T, Ozaki N, Matsumoto A, Nogawa J, Kinoshita Y, Suzuki T, Iwata N, Yamamoto Y, Okada T, Sadato N: **A variant C178T in the regulatory region of the serotonin receptor gene HTR3A modulates neural activation in the human amygdala.** *J Neurosci* 2005, **25**:6460-6.
42. Millan MJ: **Descending control of pain.** *Prog Neurobiol* 2002, **66**:355-474.
43. Alhaider AA, Lei SZ, Wilcox GL: **Spinal 5-HT₃ receptor-mediated antinociception: possible release of GABA.** *J Neurosci* 1991, **11**:1881-8.
44. Danzebrink RM, Gebhart GF: **Evidence that spinal 5-HT₁, 5-HT₂ and 5-HT₃ receptor subtypes modulate responses to noxious colorectal distension in the rat.** *Brain Res* 1991, **538**:64-75.
45. Dubin AE, Huvar R, D'Andrea MR, Pyati J, Zhu JY, Joy KC, Wilson SJ, Galindo JE, Glass CA, Luo L, Jackson MR, Lovenberg TW, Erlander MG: **The pharmacological and functional characteristics of the serotonin 5-HT(3A) receptor are specifically modified by a 5-HT(3B) receptor subunit.** *J Biol Chem* 1999, **274**:30799-810.
46. Liu MT, Rayport S, Jiang Y, Murphy DL, Gershon MD: **Expression and function of 5-HT₃ receptors in the enteric neurons of mice lacking the serotonin transporter.** *Am J Physiol Gastrointest Liver Physiol* 2002, **283**:1398-411.
47. McEwen BS: **Invited review: estrogens effects on the brain: multiple sites and molecular mechanisms.** *J Applied Physiology* 2001, **91**:2785-801.
48. Sakai Y, Nishikawa M, Leyton M, Benkelfat C, Young SN, Diksic M: **Cortical trapping of alpha-[(11)C]methyl-1-tryptophan, an index of serotonin synthesis, is lower in females than in males.** *Neuroimage* 2006, **33**:815-24.
49. Labus JS, Naliboff BN, Fallon J, Berman SM, Suyenobu B, Bueller JA, Mandelkern M, Mayer EA: **Sex differences in brain activity during aversive visceral stimulation and its expectation in patients with chronic abdominal pain: a network analysis.** *Neuroimage* 2008, **41**:1032-43.
50. Barnes NM, Hales TG, Lummis SC, Peters JA: **The 5-HT₃ receptor-the relationship between structure and function.** *Neuropharmacology* 2009, **56**:273-84.

51. Houghton LA: **Evidence of abnormal rectal sensitivity in IBS.** In *Irritable Bowel Syndrome: Diagnosis and Treatment*. Edited by: Camilleri M, Spiller R. London: WB Saunders; 2002:69-76.
52. de Vries D, ter Linde J, van Herwaarden M, Smout M, Samsom M: **Serotonin receptor 3a polymorphism C178t is associated with visceral hypersensitivity in GERD [abstract].** *Gastroenterology* 2007, **132**:A276.
53. Gatt JM, Williams LM, Schofield PR, Dobson-Stone C, Paul RH, Grieve SM, Clark CR, Gordon E, Nemeroff CB: **Impact of the HTR3A gene with early life trauma on emotional brain networks and depressed mood.** *Depress Anxiety* 2010, **27**:752-9.
54. Yamada K, Hattori E, Iwayama Y, Ohnishi T, Ohba H, Toyota T, Takao H, Minabe Y, Nakatani N, Higuchi T, Detera-Wadleigh SD, Yoshikawa T: **Distinguishable haplotype blocks in the HTR3A and HTR3B region in the Japanese reveal evidence of association of HTR3B with female major depression.** *Biol Psychiatry* 2006, **60**:192-201.

Pre-publication history

The pre-publication history for this paper can be accessed here:
<http://www.biomedcentral.com/1471-2350/12/140/prepub>

doi:10.1186/1471-2350-12-140

Cite this article as: Mujakovic *et al.*: Serotonin receptor 3A polymorphism c.-42C > T is associated with severe dyspepsia. *BMC Medical Genetics* 2011 **12**:140.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

